GLP-HM1N123-100μg / 询价
GLP-HM1N123-100μg x 5 / 询价
GLP-HM1N123-100μg x 10 / 询价
- 客服电话
- 技术支持
FITC-equivalent Human GLP-1R Protein-Nanodisc
Recombinant FITC-equivalent Human GLP-1R Protein-Nanodisc is expressed from HEK293 with His tag at the C-terminus.It contains Met1-Ser463 [Accession | P43220].
The protein has a predicted MW of 80.9 kDa.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
Less than 1EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS (pH 7.4). Notice: Not recommended for immunization.
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Immobilized Anti-GLP-1R Antibody, hFc Tag at 5μg/ml(100μl/well) on the plate. Dose response curve for FITC-equivalent Human GLP-1R Nanodisc, His Tag with the EC50 of 0.36μg/ml determined by ELISA (QC Test).
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). GLP-1R emerged as an important pharmacological target for addressing T2DM, as it actively contributes to maintaining glucose homeostasis while promoting both β cell proliferation and insulin release. The impact of GLP-1R agonists such as semaglutide extends beyond diabetes control: they play a multifaceted role in regulating blood glucose levels by reducing hunger, moderating food intake, and managing body weight. Notably, GLP-1R agonists inhibit cancer progression in some malignant tumors.
GLP-1 receptor; GLP-1-R; GLP-1R; GLP1R
Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Büsselberg D. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev. 2024 May 27. doi: 10.1007/s10555-024-10192-9. Epub ahead of print. PMID: 38801466.
